Fact CheckerSign in

NCT07358611Recruiting

Non-invasive Mapping-Guided Atrial Fibrillation Ablation

ELectrocardiographic Imaging-guided Substrate Ablation in Patients With Atrial Fibrillation - a PILOT Study of a Personalized Therapy

Source: ClinicalTrials.gov · Last updated 8 Jul 2026

Brief summary (registry, in English)

The goal of this pilot study is to test if noninvasive global mapping can guide catheter ablation defining personalized targets and improve the therapy of atrial fibrillation. It will also test the safety of such an approach. The main questions it aims to answer are: * Does ablation of targets defined by noninvasive global mapping improve rates of acute atrial fibrillation termination? * Does such a personalized ablation approach reduce arrhythmia recurrence rates? Researchers will compare the results of the personalized ablation approach with comparable patients that had undergone a conventional "empirical" ablation approach (pulmonary vein isolation). Participants will: * Undergo a personalized catheter ablation approach employing both a noninvasive global mapping system and a conventional intracardiac mapping system * Visit the clinic 3, 6 and 12 months after ablation for clinical follow-up * Schedule a telephone visit 9 and 24 months after ablation for clinical follow-up

Status (registry)
Recruiting
Study type
Interventional
Enrollment
30 (estimated)
First submitted
14 Jan 2026
Start date
31 Jan 2026
Primary completion date
31 Dec 2026
Lead sponsor
Hospital Clinic of Barcelona
NCT number
NCT07358611

What you commit to

  • Study type: Interventional
  • Planned participants: 30
  • From 31 Jan 2026 to the primary completion date, 31 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous cardiac ablation
  • Previous stroke/TIA

Other illness

  • Dermal disease or hypersensitivity predisposing for skin irritation or exanthema

Lab values

  • Severe left ventricular dysfunction (LVEF \<35%)
  • Renal failure (GFR \<30 ml/min)

Age

  • Age \<18 years

Other

  • Pregnancy or lactation

Who the study is looking for

  • Ablation-naïve patients with:
  • Persistent AF planned for catheter ablation plus
  • Left atrial enlargement (LA diameter ≥45 mm or LA volume index ≥35ml/m2 or LA area ≥20 cm2)

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital Clinic, University of Barcelona
Coordinator of this site? Confirm its status
BarcelonaSpainRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.